
His boss said his talents were 'wasted' at work—so he co-founded a company that sold for $29 billion
"My parents being retail entrepreneurs always taught me the intricacies of how to trade, how to run in retail," 35-year-old tells CNBC Make It. "So I do really feel retail is in my blood."
As a teenager, he started selling jewelry from his family's company on eBay and eventually on a standalone website for the business. But after college, Molnar wasn't sold on entrepreneurship as his career path.
"The universe told me that I should get a finance job given my commerce degree, my business degree, and so I really tried to make that a reality," he says.
His jewelry business became something of an obstacle in that pursuit, however. Molnar says he would apply for investment banking jobs and companies would see his jewelry business listed on his CV and ask why he would bother doing anything else.
"They'd say, 'Well, but why are you coming to get a job? You have a great business,'" he says. "It's like this weird paradigm that the world told me to get a job. But actually the truth was, I should have been an entrepreneur, but I got the job."
After he started working at Australian venture capital firm, M.H. Carnegie & Co. in 2011, his boss became an outspoken champion for Molnar's entrepreneurial pursuits.
Mark Carnegie, the firm's founder, would come in "every morning" and ask Molnar how much jewelry he had sold that day, he says. The website was bringing in around 2 million Australian dollars, or just over 2 million USD in annual revenue at the time, Molnar says.
As a thought exercise, Carnegie asked Molnar what he would do if he gave him a million dollars to grow his jewelry business, Molnar says.
"He really pushed me to be an entrepreneur," he says. "He basically said to me, 'Look, I think you're wasted right now being at my company. I will save your job for a year to give you the confidence to go and be an entrepreneur, but you will never come back.'"
So he left the firm in 2012 and Carnegie was right — Molnar didn't return to working in venture capital. Instead, he continued running his online jewelry business and started working on a new venture with his neighbor, Anthony Eisen. Together they launched Afterpay, a buy now, pay later company, in 2014.
Just seven years later in August 2021, their company was acquired by Jack Dorsey's fintech services company, Square, which would soon rebrand to Block. The firm purchased Afterpay for $29 billion.
Though he had early entrepreneurial inclinations, Molnar chose the regular job route at first because he wanted the stability, regular income and "security of knowing that you're going to be able to take care of your family" a full-time job can provide.
Early in his entrepreneurial journey, founders he tapped for advice told him the success rate for new businesses is "really low," he says. Buy now, pay later lenders are fairly ubiquitous in retail now, but back in 2014 they were rare, and virtually nonexistent in Australia. Afterpay would have to sell consumers on a new way to shop and spend.
"I knew millennials needed another option," Molnar says. "Credit cards were not going to be the way they wanted to manage their spending and each time I shared the vision and opportunity with people, I was more and more convinced that we had to bring the idea to life."
Still, it took Carnegie's challenge — and assurance — for Molnar to take the leap.
"Even though I feel like an entrepreneur through and through...it took the right people to give me the confidence," he says.
He wouldn't go back and change his trajectory if he could, he says. He learned a lot working at the venture capital firm and says the trial-and-error period of many early entrepreneurs may have discouraged him or held him back. On top of the confidence Carnegie helped instill in him, this lack of hindsight was a "superpower," he says.
"I had nothing telling me no, I had no past that was giving me muscle memory to say that like this shouldn't work," Molnar says. "I think you make the wrong decision sometimes when you stop trusting your intuition — when you're swayed by moments in your life and your journey, that probably wouldn't have swayed you before."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Los Angeles Times
2 hours ago
- Los Angeles Times
Culver City Plant-Based Food Manufacturer Daring Foods Acquired by Australian Firm
Daring Foods, a Culver City-based food manufacturer focused on plant-based meat substitutes, was acquired by Australian firm V2food for an undisclosed amount. The company had generated annual revenue of about $30 million from products sold in thousands of stores that include major grocers Whole Foods and Walmart. 'Daring has built an incredible, consumer-loved brand with strong reach across the U.S., and combining that with our food technology creates immediate opportunities to accelerate our mission to be one of the global leaders in plant-based protein,' said Tim York, chief executive of V2food, in a statement. The company was founded in 2018 and raised more than $120 million to develop and expand its product line. It reached a valuation of $329 million in 2021. Information for this article was sourced from V2food.


Time Business News
4 hours ago
- Time Business News
Next-Generation Approaches to Hematologic Malignancies
Hematologic malignancies are cancer that affect blood, bone marrow, and lymphatic systems including leukemia, lymphoma and multiple myeloma. These cancers disrupt normal blood cell production and immune function. The growth of the hematologic malignancy market is inspired by increasing the prevalence of global cancer, increasing target remedies and immunotherapy, progression in clinical technologies and expanding research in individual medicine. Additionally, increasing awareness, better healthcare infrastructure, and oncology contribute to more investment market expansion in drug development. Key Growth Drivers and Opportunities Increasing the Prevalence of Global Cancer: The increasing global spread of cancer greatly enhances the growth of the market of hematologic malignancies, as blood -related cancer, such as leukemia, lymphoma and multiple myeloma, become a large part of cancer worldwide. As more individuals are affected by these conditions, there is an increasing demand for accurate diagnosis, advanced treatment options and long -term disease management solutions. In cases, this increase encourages drug companies and research institutes to invest in innovative remedies such as targeted treatment, immunotherapy and CAR-T cell therapy. Additionally, high cancer phenomena motivate governments and healthcare systems to increase screening programs and to reach oncology. Challenges Hematologic malignancies markets face several borders, including high cost of advanced treatments such as car-T cell treatment and targeted drugs, which can restrict access to patients in low- and moderate-income areas. Complex regulatory approval, long clinical testing procedures, and severe side effects or ability to resist also face significant challenges. Additionally, limited availability of specialized clinical equipment and lack of efficient health care professionals in some fields obstruct timely and accurate diagnosis, overall treatment affects results and slows down market development. Innovation and Expansion Kyowa Kirin and Kura Oncology Collaborate to Create Ziftomenib for Acute Leukemias In November 2024, in order to develop and market ziftomenib, Kura's selective oral menin inhibitor, which is being researched for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced they have formed a global strategic partnership. Kura will get USD 330 million up front as part of the deal, and it anticipates receiving up to USD 420 million in near-term milestone payments, including one when ziftomenib is introduced in the monotherapy relapsed/refractory (R/R) context. Merck Launched Phase III Trials for Novel Treatments for Blood Disorders and Cancer In January 2024, With the start of pivotal Phase III studies for four new candidates for solid tumors and hematologic malignancies, Merck's strong oncology and hematology portfolio is progressing. Essential thrombocythemia (ET), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), non-small cell lung cancer (NSCLC), some patients with endometrial carcinoma who have already received treatment, and metastatic castration-resistant prostate cancer (mCRPC) are among the conditions for which the company announced active enrollment for investigational medications. The firm is committed to ongoing research to broaden our portfolio of oncology treatments in order to continue addressing unmet needs in cancer care. The company has a rich history of transforming groundbreaking science into medicines that save and enhance lives worldwide. Inventive Sparks, Expanding Markets The key players operating the hematologic malignancies market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS

Business Insider
5 hours ago
- Business Insider
Claude Code turned a 3-week project into a 2-day task — but nearly broke it
Hugh Williams, former Google and eBay engineering VP, recently spent two days deep in the weeds with Claude Code, Anthropic's AI-powered coding assistant. His verdict? "It's like being a carpenter who suddenly has awesome power tools." Williams built a fully functional system running on AWS in 48 hours, a task he says would normally take at least three weeks. He didn't just write code; he learned a new graph database (AWS Neptune) on the fly, delivering clean, modular, and scalable output. Claude Code had problems, too, though. Williams warned that every hour or so, the coding assistant compressed its conversation context, and things broke. "I learnt to wrap up a 'milestone,' update the README, and start a new conversation afresh before compaction occurs," he wrote on LinkedIn. Williams also made the now-classic mistake of asking Claude to "clean up" code directories, and watched it wipe out important features, working code, and data in one stroke. "I learnt the hard way to back up code every hour or so manually, so I could go back to previous versions when things went awry," he explained. Occasionally, Claude Code would add random extra or duplicative features, so he needed to inspect the code holistically every hour or so to make sure his projects were headed in the right direction. Still, Williams believes Claude Code is a true accelerator for those who already know how to code. For junior devs or non-coders? Not yet. He estimates Claude Code can already take on 50% of the workload for a seasoned engineer, and that might top out at roughly 75%, a productivity jump with serious implications. Bottom line: For experienced builders, Claude Code is here, and it's powerful. Just don't forget to back up your work!